DarioHealth Reports First Quarter 2021 Results and Operational Highlights
USA - English
Announced acquisition of Upright Technologies, expanding into the musculoskeletal and related pain conditions markets
Generated Q1 revenue growth of 73% over Q4 2020 and 116% over Q1 2020, driven by organic growth and consolidation of Upright Technologies revenues effective February 2, 2021
GAAP gross margin was 30.1% in the first quarter, excluding acquisition related amortizations Q1 2021 product gross margin nearly doubled to 44.7% as compared to 24.2% in Q4 2020
Ended the first quarter 2021 with cash and cash equivalents of $81.1 million
Company to host conference call and webcast 8:30 am ET tomorrow.
News provided by
Share this article
Share this article
DarioHealth Study Examines Connection Between Personalization and Sustained Behavior Change in Digital Health
USA - English
News provided by
Share this article
Share this article
NEW YORK, March 2, 2021 /PRNewswire/ DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, today announced the results of a new clinical study that have been published in the
Journal of Medical Internet Research (JMIR) Diabetes. The paper is titled Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study.
In the world of digital health, the focus has long been the differences between people - analyzing data, patterns, and demographics to create personas that match like individuals. The idea behind many current digital health solutions is that personalization is your fingerprint , but while fingerprints don t change, people do. What an individual liked and was willing to try yesterday may not be what they are willing to
Dr. Valley s research focuses on understanding and improving decision-making in the intensive care unit (ICU). His primary line of research seeks to identify the patients most likely to benefit from intensive care, allowing clinicians to safely triage patients between the ICU and the general ward. Ultimately, he hopes to identify ICU-based therapies that can be transferred to the general ward to improve hospital efficiency and reduce healthcare costs. Dr. Valley’s research interests also include ensuring all critically ill individuals receive the best possible care, regardless of where they are hospitalized.
Experience
Patients taking immunosuppressive drugs did not have worse COVID-19 outcomes
People taking immunosuppressive drugs to prevent organ transplant rejection or to treat inflammatory or autoimmune diseases do not fare worse than others on average when they are hospitalized with COVID-19, according to a study from researchers at the Johns Hopkins Bloomberg School of Public Health.
Estimates suggest that there are approximately 10 million immunocompromised people in the U.S. alone. Suppression of the immune system has been considered a potentially major risk factor for severe and fatal COVID-19 because it could allow the SARS-CoV-2 virus to spread unchecked in the body.
Largest-ever study finds low complication rates in children who wear soft contact lenses
The largest-ever retrospective study of its kind has found very low complication rates in children who wear soft contact lenses, similar to rates in adults. The newly-published outcomes offer eye care professionals (ECPs) valuable real-world information to better counsel parents and caregivers as they consider proven myopia management options to help slow myopia progression.
Adverse Event Rates in The Retrospective Cohort Study of Safety of Paediatric Soft Contact Lens Wear: the ReCSS Study will appear in the January 2021 issue of
Ophthalmic & Physiological Optics, the peer reviewed journal of the UK College of Optometrists. It is now available in pre-press form via open access.